iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Zydus Life gets USFDA nod for depression and herpes drugs

1 Sep 2022 , 12:48 PM

Venlafaxine is used to treat depression, anxiety, panic attacks and social anxiety disorder. It is expected to improve mood and energy levels in patients. The medication is also expected to decrease fear, anxiety, unwanted thoughts and the number of panic attacks. According to IQVIA MAT July 2022, Venlafaxine extended-release tablets had annual sales of $46 million in the United States. Pregabalin extended-release tablets are used to treat pain caused by nerve damage due to diabetes or shingles (herpes zoster) infection. Pregabalin extended-release tablets had annual sales of $3 million in the United States according to IQVIA MAT June 2022. Both the drugs will be manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India. The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in financial year 2003-04. Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit fell 11.7% to Rs 518.3 crore on a 1.8% increase in total income from operations to Rs 4,072.7 crore in Q1 FY23 over Q1 FY22. Shares of Zydus Lifesciences declined 0.90% to Rs 374.65 on the BSE.Powered by Capital Market – Live News

Related Tags

  • capital market
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.